The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Omega-3 Fatty Acid Supplementation Improves Endothelial Function in Primary Antiphospholipid Syndrome: A Small-Scale Randomized Double-Blind Placebo-Controlled Trial
|
|---|---|
| Published in |
Frontiers in immunology, March 2018
|
| DOI | 10.3389/fimmu.2018.00336 |
| Pubmed ID | |
| Authors |
Sheylla M. Felau, Lucas P. Sales, Marina Y. Solis, Ana Paula Hayashi, Hamilton Roschel, Ana Lúcia Sá-Pinto, Danieli Castro Oliveira De Andrade, Keyla Y. Katayama, Maria Claudia Irigoyen, Fernanda Consolim-Colombo, Eloisa Bonfa, Bruno Gualano, Fabiana B. Benatti |
| Abstract |
Endothelial cells are thought to play a central role in the pathogenesis of antiphospholipid syndrome (APS). Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation has been shown to improve endothelial function in a number of diseases; thus, it could be of high clinical relevance in APS. The aim of this study was to evaluate the efficacy of n-3 PUFA supplementation on endothelial function (primary outcome) of patients with primary APS (PAPS). A 16-week randomized clinical trial was conducted with 22 adult women with PAPS. Patients were randomly assigned (1:1) to receive placebo (PL, n = 11) or n-3 PUFA (ω-3, n = 11) supplementation. Before (pre) and after (post) 16 weeks of the intervention, patients were assessed for endothelial function (peripheral artery tonometry) (primary outcome). Patients were also assessed for systemic markers of endothelial cell activation, inflammatory markers, dietary intake, international normalized ratio (INR), and adverse effects. At post, ω-3 group presented significant increases in endothelial function estimates reactive hyperemia index (RHI) and logarithmic transformation of RHI (LnRHI) when compared with PL (+13 vs. -12%, p = 0.06, ES = 0.9; and +23 vs. -22%, p = 0.02, ES = 1.0). No changes were observed for e-selectin, vascular adhesion molecule-1, and fibrinogen levels (p > 0.05). In addition, ω-3 group showed decreased circulating levels of interleukin-10 (-4 vs. +45%, p = 0.04, ES = -0.9) and tumor necrosis factor (-13 vs. +0.3%, p = 0.04, ES = -0.95) and a tendency toward a lower intercellular adhesion molecule-1 response (+3 vs. +48%, p = 0.1, ES = -0.7) at post when compared with PL. No changes in dietary intake, INR, or self-reported adverse effects were observed. In conclusion, 16 weeks of n-3 PUFA supplementation improved endothelial function in patients with well-controlled PAPS. These results support a role of n-3 PUFA supplementation as an adjuvant therapy in APS. Registered at http://ClinicalTrials.gov as NCT01956188. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 10% |
| Unknown | 9 | 90% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 90% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 24% |
| Researcher | 7 | 9% |
| Student > Ph. D. Student | 6 | 8% |
| Student > Master | 5 | 7% |
| Student > Doctoral Student | 3 | 4% |
| Other | 13 | 18% |
| Unknown | 22 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 24% |
| Biochemistry, Genetics and Molecular Biology | 7 | 9% |
| Nursing and Health Professions | 6 | 8% |
| Immunology and Microbiology | 4 | 5% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 8 | 11% |
| Unknown | 28 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 June 2023.
All research outputs
#6,644,452
of 26,414,132 outputs
Outputs from Frontiers in immunology
#6,931
of 33,172 outputs
Outputs of similar age
#104,758
of 350,176 outputs
Outputs of similar age from Frontiers in immunology
#201
of 683 outputs
Altmetric has tracked 26,414,132 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 33,172 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,176 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 683 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.